Skip to main content
Article thumbnail
Location of Repository

Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast

By G P Boland, A Mckeown, K C Chan, R Prasad, W F Knox and N J Bundred
Topics: Molecular and Cellular Pathology
Publisher: Nature Publishing Group
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1998). (2001b) HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61: 8452–8458 Early Breast Cancer Trialists’ Collaborative Group
  2. (1993). Distribution of estrogen receptor in ductal carcinoma in situ of the breast. Surgery 113: 134–137
  3. (2002). Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of
  4. (2001). MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors. Histol Histopathol 16: 399–406 Harper-Wynne
  5. (2000). Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
  6. (2002). The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.